Whole-genome sequencing (WGS) of experimental breast cancer models and selected primary and relapsed tumor samples revealed that active APOBEC3 mutations contribute to resistance against endocrine and targeted therapies, primarily through RB1 mutations, leading to its functional impairment [69]. Here, RB1 is linked to breast cancer.